- Home
- PROK vs REFI Comparison
PROK vs REFI Comparison
Compare PROK & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- REFI
- Stock Information
- Founded
- PROK 2015
- REFI 2021
- Country
- PROK United States
- REFI United States
- Employees
- PROK N/A
- REFI N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- REFI Real Estate Investment Trusts
- Sector
- PROK Health Care
- REFI Real Estate
- Exchange
- PROK Nasdaq
- REFI Nasdaq
- Market Cap
- PROK 334.8M
- REFI 274.3M
- IPO Year
- PROK N/A
- REFI 2021
- Fundamental
- Price
- PROK $2.45
- REFI $13.37
- Analyst Decision
- PROK Buy
- REFI Strong Buy
- Analyst Count
- PROK 5
- REFI 3
- Target Price
- PROK $6.25
- REFI $20.00
- AVG Volume (30 Days)
- PROK 2.4M
- REFI 130.8K
- Earning Date
- PROK 11-11-2025
- REFI 11-06-2025
- Dividend Yield
- PROK N/A
- REFI 15.44%
- EPS Growth
- PROK N/A
- REFI N/A
- EPS
- PROK N/A
- REFI 1.84
- Revenue
- PROK $527,000.00
- REFI $56,608,781.00
- Revenue This Year
- PROK $265.05
- REFI $9.93
- Revenue Next Year
- PROK N/A
- REFI $4.99
- P/E Ratio
- PROK N/A
- REFI $7.26
- Revenue Growth
- PROK N/A
- REFI 2.58
- 52 Week Low
- PROK $0.46
- REFI $12.76
- 52 Week High
- PROK $7.13
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- PROK 50.33
- REFI 39.83
- Support Level
- PROK $2.12
- REFI $13.08
- Resistance Level
- PROK $3.05
- REFI $14.57
- Average True Range (ATR)
- PROK 0.23
- REFI 0.32
- MACD
- PROK 0.03
- REFI -0.12
- Stochastic Oscillator
- PROK 35.48
- REFI 19.46
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.